Depression and Immune Function in Multiple Sclerosis (MS)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

104 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-11-30

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Depression is one of the most common symptoms of multiple sclerosis (MS) with a life-time prevalence of major depressive disorder (MDD) of up to 50%. Depression occurs more frequently in MS than in other chronic diseases including other neurological and inflammatory disorders and may contribute to lower quality of life, cognitive problems, difficulties at work, and poorer long term health outcomes. Despite its clinical relevance, the biological mechanisms which may be responsible for the high risk for MS patients to develop depression are unknown.

In this observational study, investigators explore the molecular mechanisms responsible for the impaired regulation of immune cells in relapsing-remitting (RR) MS patients with depression. Investigators will compare the molecular and phenotypical profile of immune cells obtained from RRMS patients with clinical depression (n=50), matched MS patients who do not suffer from depression (n=50) as well as matched healthy controls (n=50) and matched patients with depression but without a comorbid neurological disorder (n=50).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis

NCT01079975

Multiple Sclerosis

COMPLETED

Cerebral Neuroinflammation During Major Depressive Episode

NCT03314155

Depressive Disorder

UNKNOWN NA

Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation

NCT05909267

Depressive Disorder, Major

RECRUITING NA

The Pathogenesis of Depression - Possible Autoimmune Mechanisms

NCT05293899

Depression Autoimmune Diseases

RECRUITING

Immune Activation, Neural Plasticity and Depression

NCT06306248

Mood Disorders Major Depressive Disorder Sleep Deprivation

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis Depressive Disorder, Major

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy controls

No intervention

Intervention Type OTHER

RRMS

Relapsing-Remitting Multiple Sclerosis

No intervention

Intervention Type OTHER

RRMS+MDD

Relapsing-Remitting Multiple Sclerosis and Major Depressive Disorder

No intervention

Intervention Type OTHER

MDD

Major Depressive Disorder

No intervention

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Relapsing remitting MS by McDonald Criteria (for RRMS and RRMS+MDD groups).
* Currently meeting diagnostic criteria for Major Depressive Disorder (for MDD and RRMS+MDD groups)
* Age 18-55.
* On stable treatment regime, either untreated or on disease modifying therapy (DMT) for \> 6 months

Exclusion Criteria

* Secondary-progressive or primary progressive MS.
* Substance abuse for more than 6 months.
* Pregnancy
* Use of steroids or vaccination or infections in the previous 3 months.
* Signs of serious psychiatric pathology other than depression including schizophrenia, bipolar disorder or developmental and learning disorders including disorders on the autism spectrum
* Antidepressant medication.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes